**Various Embargoes**
THE LANCET JOURNALS: Papers being presented at the American Diabetes Association [ADA] 85th Scientific Sessions
The following papers published across The Lancet Group will be presented at the American Diabetes Association [ADA] 85th Scientific Sessions. The conference will take place from Friday 20 June through Monday 23 June 2025 in Chicago, Illinois, USA.
Contact details for corresponding authors are provided should you wish to arrange an interview with the authors. Funding information is listed on the first page of each Article.
Highlighted content:
**Embargo: 00.30 Saturday 21st June [UK time] / 6.30pm [US CT] Friday 20th June 2025** Please note the unusual embargo time.
Peer-reviewed / Randomised Controlled Trial x2 / People
The Lancet: Amycretin shows promise as a new weight management therapy, early phase clinical trials confirm
Amycretin, a novel weight management medication, showed promise in two new, early-phase clinical trials published in The Lancet. Amycretin is designed to target two specific receptors in the body — the GLP-1 receptor and the amylin receptor – to help control blood sugar and appetite. Because this medicine can activate both receptors at the same time, researchers say it has the potential to better manage conditions such as overweight and obesity compared to medicines that target just one receptor.
A phase 1b/2a trial tested the safety and tolerability of once-weekly subcutaneous (under the skin and above the muscle) injections of amycretin in 125 adults with overweight or obesity. Participants who received the highest doses (up to 60 mgs) reported body weight reductions of up to 24.3% after 36 weeks of treatment. A high frequency of gastrointestinal adverse effects (including nausea and vomiting) were reported although these were mostly mild to moderate and typically resolved by the end of treatment. The medication also showed signs of improving blood sugar levels, but further trials will be needed to confirm the role of amycretin in this aspect of diabetes management.
The second phase 1 trial investigated oral amycretin taken daily over 12 weeks in 144 participants. This first-in-human trial confirmed amycretin’s safety and tolerability, with mild to moderate gastrointestinal side effects, including loss of appetite, nausea, and vomiting. Participants taking the highest dose (100 mgs per day), of oral amycretin lost an average of 13.1% of their body weight after 12 weeks, suggesting oral amycretin could be a promising weight management medication.
Together, these studies suggest amycretin – both as a once-weekly injection and as a daily oral medication – could be a promising approach for treating overweight, obesity, and type 2 diabetes, though larger studies will be needed to confirm these findings.
In a linked Comment to the two articles, Professor Tricia Tan and Dr Bernard Khoo (who were not involved in the studies), highlight the need to look beyond weight loss in obesity management to understand if treatments reduce the risk of cardiovascular disease and other conditions linked to obesity.
Paper 1 (subcutaneous amycretin) available under embargo at (journalist only link): https://info.thelancet.com/hubfs/Press%20embargo/ADA%202025/SCAmycretin.pdf
Paper 2 (oral amycretin) available under embargo at (journalist only link): https://info.thelancet.com/hubfs/Press%20embargo/ADA%202025/OralAmycretin.pdf
Linked comment available under embargo at (journalist only link): https://info.thelancet.com/hubfs/Press%20embargo/ADA%202025/AmycretinLC.pdf
Paper 1 appendix: https://info.thelancet.com/hubfs/Press%20embargo/ADA%202025/25tl3216_Dahl_Appendix.pdf
Paper 2 appendix: https://info.thelancet.com/hubfs/Press%20embargo/ADA%202025/25tl0293_appendix.pdf
Once the embargo lifts, please use these links as the one above will be deactivated:
Paper 1 (subcutaneous amycretin): https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01185-7/fulltext
Paper 2 (oral amycretin): https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01176-6/fulltext
For interviews with the authors of both studies, contact:toig@novonordisk.com
-
**Embargo: 20:45 [UK time] / 02:45pm [US CT] Saturday 21st June 2025** Please note the unusual embargo time.
Peer-reviewed / Randomised Controlled Trial / People
The Lancet Diabetes & Endocrinology: Ecnoglutide, a new medication for weight management, is a safe and effective, trial confirms
Ecnoglutide,a novel type of weight loss medication that may help lower blood sugar by targeting a specific receptor in the body, is a safe and effective treatment option for weight management in individuals with overweight or obesity without diabetes, confirms a phase 3 randomised controlled trial (RCT) published in The Lancet Diabetes & Endocrinology journal. The trial found that those taking ecnoglutide lost between 9% and 13% of their body weight on average, after 40 weeks of treatment, compared to almost no weight change in the placebo group, suggesting ecnoglutide is as safe and effective as other currently approved GLP-1 receptor agonists, such as semaglutide or tirzepatide.
Ecnoglutide is a cyclic adenosine monophosphate (cAMP)-biased glucagon-like peptide-1 (GLP-1) receptor agonist that works by primarily activating a singular pathway inside cells—potentially leading to more targeted therapeutic effects (such as improved insulin secretion and reduction in bodyweight). The researchers say it may be more effective than other, similar weight loss medications and is just as safe. While ecnoglutide had shown promise in smaller trials, this is the first phase 3 trial to investigate its efficacy and safety in individuals with overweight or obesity.
The SLIMMER trial involved 664 adults with overweight or obesity without diabetes in China who were randomly assigned to receive a once weekly dose of ecnoglutide (either 1.2, 1.8, or 2.4 mg) or a placebo over 48 weeks. The trial also found that a much higher percentage of people on ecnoglutide lost at least 5% of their body weight compared to those on placebo (77–87% compared to 16%) over 40 weeks of treatment. Ecnoglutide was found to be similarly safe as approved GLP-1 receptor agonists, with the most common side effects being mild to moderate digestive system related issues, like nausea; however, very few people stopped treatment because of side effects.
The authors highlight that those on the higher doses of ecnoglutide continued to experience weight loss up to week 48, indicating that even greater weight loss may be achievable with extended ecnoglutide treatment. They suggest that ecnoglutide may serve as a treatment option for individuals who fail to achieve sufficient weight reduction with existing GLP-1 receptor agonists or need to achieve a more drastic target of body weight reduction.
Article available under embargo at (journalist only link): https://info.thelancet.com/hubfs/Press%20embargo/ADA%202025/EcnoglutideADA.pdf
Linked comment available under embargo at: https://info.thelancet.com/hubfs/Press%20embargo/ADA%202025/EcnoglutideADALC.pdf
Appendix: https://info.thelancet.com/hubfs/Press%20embargo/ADA%202025/25tlde0300_Appendix.pdf
Once the embargo lifts, please use this link as the one above will be deactivated: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00141-X/fulltext
For interviews with the authors, please contact: jiln@bjmu.edu.cn
-
For the below additional Lancet content publishing at ADA, please see: https://drive.google.com/drive/folders/1lqTaGPyhN2CiXzdri5WZ2Ux3QpISZgEp?usp=sharing
**Embargo: 19.30 UK time /13.30 pm CT Sunday 22nd June**
- Once-weekly insulin efsitora alfa versus once-daily insulin glargine in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a randomised clinical trial
- Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3 randomised non-inferiority trial
**Embargo: 14.00 UK time / 8.00 am CT Monday 23rd June**
- A three paper Series on early-onset type 2 diabetes
Journal
The Lancet